Genmab A/S
CSE:GMAB
Genmab A/S
Total Current Liabilities
Genmab A/S
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Total Current Liabilities
kr5.3B
|
CAGR 3-Years
50%
|
CAGR 5-Years
41%
|
CAGR 10-Years
23%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Current Liabilities
kr403.5m
|
CAGR 3-Years
6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Current Liabilities
€907.9m
|
CAGR 3-Years
108%
|
CAGR 5-Years
80%
|
CAGR 10-Years
53%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Current Liabilities
kr2.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Current Liabilities
kr20.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Saniona AB
STO:SANION
|
Total Current Liabilities
kr105.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
32%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Total Current Liabilities?
Total Current Liabilities
5.3B
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Total Current Liabilities amounts to 5.3B DKK.
What is Genmab A/S's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
23%
Over the last year, the Total Current Liabilities growth was 114%. The average annual Total Current Liabilities growth rates for Genmab A/S have been 50% over the past three years , 41% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet